Hyperphosphatemia
Drug research and approvals for hyperphosphatemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 9 studies of hyperphosphatemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 1 approved and 3 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 9
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 3
Recruiting Now
Newest start dates first, of 9 recruiting on ClinicalTrials.gov ↗- Phosphate in Acute PancreatitisNCT07681050 · Phase 2 · Duke University · starts Jul 9, 2026
- A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With…NCT06712654 · Phase 2 · R1 Therapeutics · starts Jun 1, 2026
- A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal DialysisNCT07548853 · Phase 3 · Taisho Pharmaceutical Co., Ltd. · starts May 13, 2026
- A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate BindersNCT07285291 · Phase 3 · Taisho Pharmaceutical Co., Ltd. · starts Jan 9, 2026
- A Long-term Study of TS-172 in Hyperphosphatemia Patients on HemodialysisNCT07285304 · Phase 3 · Taisho Pharmaceutical Co., Ltd. · starts Dec 1, 2025
- A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and ChinaNCT06933472 · Phase 3 · Alebund Pharmaceuticals · starts Jun 13, 2025
- Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil CapsuleNCT06206135 · Not reported · LG Chem · starts Dec 21, 2023
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of…NCT04278404 · Not reported · Duke University · starts Mar 5, 2020
- Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)NCT03573089 · Not applicable · The University of Queensland · starts Dec 10, 2019
Drug Pipeline
4 approved, 3 in phase 3, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Sevelamer, Ferric oxyhydroxide, Ferric citrate anhydrous, Colestilan chloride
- Tenapanor
- Phase 3 Sodium/hydrogen exchanger 3 inhibitor
- Lanthanum carbonate
- Phase 3 Phosphate sequestering agent
- Calcium carbonate
- Phase 3
- Niacinamide
- Phase 1
- Sodium polystyrene sulfonate
- Phase 1 Potassium sequestering agent
- Oxylanthanum carbonate
- Phase 1
How Its Trials Ended
149 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 50 whose ending is known, 66% met their primary endpoint, 4% missed it and 30% stopped early.
- Completed, result not reported7349%
- Met its primary endpoint3322%
- Status unknown149%
- Ongoing128%
- Stopped: other or unclear75%
- Stopped: enrollment or feasibility53%
- Stopped: funding32%
- Missed its primary endpoint21%
FDA Orphan Designations
Approved first, then open designations, newest first| Dec 10, 1990 | Phos-LoTreatment of hyperphosphatemia in end stage renal failure. | Fresenius Medical Care North America | Approved |
| Nov 14, 2023 | Tenapanor hydrochlorideTreatment of pediatric hyperphosphatemia | Ardelyx, Inc. | Designated |
| Jun 6, 1990 | Calcium carbonateTreatment of hyperphosphatemia in patients with end stage renal disease. | R & D Laboratories, Inc. | Designated |
| Jun 27, 1989 | Calcium acetateTreatment of hyperphosphatemia in end stage renal disease. | Pharmedic Company | Designated |
Medicines Authorised in the EU
Newest first| Jan 15, 2015 | Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)Sevelamer carbonate | Sanofi Winthrop Industrie | EMA ↗ |
| Aug 26, 2014 | VelphoroSucroferric oxyhydroxide | Vifor Fresenius Medical Care Renal Pharma France | EMA ↗ |
| Jun 9, 2009 | RenvelaSevelamer carbonate | Sanofi Winthrop Industrie | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA